Webinars

DEC 02, 2021 8:00 AM PST

Early identification of target candidates for pancreatic adenocarcinoma immunotherapy

Sponsored by: Miltenyi Biotec

Speaker

Event Date & Time

Date: December 2, 2021

Time: 8:00am (PDT), 11:00am (EDT)

Abstract

Effective immunotherapy of pancreatic ductal adenocarcinoma (PDAC) is hampered by the lack of suitable tumor-specific antigens. To address this challenge, we have combined high-throughput flow cytometry with high-content cyclic immunofluorescence for the early identification of target candidates for cellular immunotherapy. Within this webinar, we aim to guide the viewers through our most recently published scientific findings[1] and related cutting-edge tools, ranging from the preparation of primary and xenografted tumor specimens to the comprehensive antigen screening and deep phenotyping. [1] Schäfer, D., Tomiuk, S., Küster, L.N. et al. Identification of CD318, TSPAN8 and CD66c as target candidates for CAR T cell based immunotherapy of pancreatic adenocarcinoma. Nat Commun 12, 1453 (2021).

https://doi.org/10.1038/s41467-021-21774-4

Learning Objectives

Identify the problem of solid tumor CAR T cell therapies in that most identified tumor-associated antigens are also expressed in healthy tissue.
Discuss high-throughput flow cytometry followed by high-content immunofluorescent imaging are ideal tools for systematically screening for CAR targets.
Discuss how CD318, TSPAN8 and CD66c were identified as potential targets for CAR T cell based immunotherapy of PDAC.

Webinars will be available for unlimited on-demand viewing after live event.

LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.

Early identification of target candidates for pancreatic adenocarcinoma immunotherapy

Olaf Hardt, PhD